Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer

Endocrine-Related Cancer

Volumn 23, Issue 10, 2016, Pages 783-796

  Hamilton, Duane H ^a   Roselli, Mario ^b   Ferroni, Patrizia ^c   Costarelli, Leopoldo ^d   Cavaliere, Francesco ^d   Taffuri, Mariateresa ^d   Palena, Claudia ^a   Guadagni, Fiorella ^c,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c San Raffaele Roma Open University   (Italy)

^d San Giovanni Hospital Addolorata   (Italy)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Brachyury; TNBC; Tumor antigen; Vaccine target

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN; MESSENGER RNA; NUCLEAR PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BRACHYURY; UNCLASSIFIED DRUG; BRACHYURY PROTEIN; FETOPROTEIN; T BOX TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BREAST BIOPSY; CANCER CELL; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MIDDLE AGED; PRIMARY TUMOR; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; AGED; CELL NUCLEUS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MCF-7 CELL LINE; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CANCER VACCINES; CELL LINE, TUMOR; CELL NUCLEUS; FEMALE; FETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; T-BOX DOMAIN PROTEINS; TRIPLE NEGATIVE BREAST NEOPLASMS; UP-REGULATION;

EID: 84993939994     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-16-0037     Document Type: Article

References (46)

1. Ben-Hamo R, Gidoni M & Efroni S 2014 PhenoNet: identification of key networks associated with disease phenotype. Bioinformatics 30 2399-2405. (doi:10.1093/bioinformatics/btu199)
2. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM & Thompson EW 2008 Epithelial mesenchymal transition traits in human breast cancer cell lines. Clinical and Experimental Metastasis 25 629-642. (doi:10.1007/s10585-008-9170-6)
3. Cancer Genome Atlas Network 2012 Comprehensive molecular portraits of human breast tumours. Nature 490 61-70. (doi:10.1038/nature11412)
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 2492-2502. (doi:10.1001/jama.295.21.2492)
5. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al. 2009 Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. PNAS 106 13820-13825. (doi:10.1073/pnas.0905718106)
6. David JM, Hamilton DH & Palena C 2016 MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. Oncoimmunology 5 e1117738. (doi:10.1080/2162402X.2015.1117738)
7. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P & Narod SA 2007 Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research 13 4429-4434. (doi:10.1158/1078-0432.CCR-06-3045)
8. Du R, Wu S, Lv X, Fang H, Wu S & Kang J 2014 Overexpression of brachyury contributes to tumor metastasis by inducing epithelialmesenchymal transition in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research 33 105. (doi:10.1186/s13046-014-0105-6)
9. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J & Palena C 2010 The T-box transcription factor Brachyury promotes epithelialmesenchymal transition in human tumor cells. Journal of Clinical Investigation 120 533-544. (doi:10.1172/JCI38379)
10. Fernando RI, Castillo MD, Litzinger M, Hamilton DH & Palena C 2011 IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Research 71 5296-5306. (doi:10.1158/0008-5472.CAN-11-0156)
11. Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK & Palena C 2016 IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget 7 42031-42044. (doi:10.18632/oncotarget.9662)
12. Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, et al. 2015 The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget 6 31344-31359. (doi:10.18632/oncotarget.5181)
13. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, et al. 2010 CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. Journal of Clinical Investigation 120 485-497. (doi:10.1172/JCI39397)
14. Gupta GP & Massague J 2006 Cancer metastasis: building a framework. Cell 127 679-695. (doi:10.1016/j.cell.2006.11.001)
15. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W & Toppmeyer D 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Journal of Clinical Oncology 24 5652-5657. (doi:10.1200/JCO.2006.06.5664)
16. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J & Palena C 2013 Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 4 1777-1790. (doi:10.18632/oncotarget.1295)
17. Hamilton DH, Huang B, Fernando RI, Tsang KY & Palena C 2014 WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Research 74 2510-2519. (doi:10.1158/0008-5472.CAN-13-1894)
18. Hamilton DH, Fernando RI, Schlom J & Palena C 2015 Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody. Oncotarget 6 4853-4862. (doi:10.18632/oncotarget.3086)
19. Haro A, Yano T, Kohno M, Yoshida T, Koga T, Okamoto T, Takenoyama M & Maehara Y 2013 Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma. Annals of Surgical Oncology 20 (Supplement 3) S509-S516. (doi:10.1245/s10434-013-2914-9)
20. Heery CR, Donahue R, Lepone L, Grenga I, Richards J, Metenou S, Fernando RI, Dirmeier U, Singh H, Madan R, et al. 2015a Phase I, doseescalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses. Journal for ImmunoTherapy of Cancer 3 1-2. (doi:10.1186/2051-1426-3-s2-p132)
21. Heery CR, Singh BH, Rauckhorst M, Marte JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, et al. 2015b Phase I trial of a Yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor Brachyury. Cancer Immunology Research 3 1248-1256. (doi:10.1158/2326-6066.CIR-15-0119)
22. Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW & Palena C 2013 The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death Disease 4 e682. (doi:10.1038/cddis.2013.208)
23. Jeong H, Ryu YJ, An J, Lee Y & Kim A 2012 Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 60 E87-95. (doi:10.1111/j.1365-2559.2012.04195.x)
24. Kalluri R & Weinberg RA 2009 The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation 119 1420-1428. (doi:10.1172/JCI39104)
25. Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, Wasielewski R, Viebahn C, Kreipe H & Schumacher U 2011 Brachyury expression predicts poor prognosis at early stages of colorectal cancer. European Journal of Cancer 47 1080-1085. (doi:10.1016/j.ejca.2010.11.015)
26. Kispert A, Koschorz B & Herrmann BG 1995 The T protein encoded by Brachyury is a tissue-specific transcription factor. EMBO Journal 14 4763-4772.
27. Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH & Palena C 2013 An autocrine loop between TGF-beta1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Molecular Cancer Therapy 12 1805-1815. (doi:10.1158/1535-7163.MCT-12-1007)
28. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, et al. 2012 Dissecting the heterogeneity of triple-negative breast cancer. Journal of Clinical Oncology 30 1879-1887. (doi:10.1200/JCO.2011.38.2010)
29. Miettinen M, Wang Z, Lasota J, Heery C, Schlom J & Palena C 2015 Nuclear brachyury expression is consistent in chordoma, common in germ cell tumors and small cell carcinomas, and rare in other carcinomas and sarcomas: an immunohistochemical study of 5229 Cases. American Journal of Surgical Pathology 39 1305-1312. (doi:10.1097/PAS.0000000000000462)
30. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J & Millikan RC 2010 Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clinical Cancer Research 16 6100-6110. (doi:10.1158/1078-0432.ccr-10-1533)
31. Palena C & Hamilton DH 2015 Immune targeting of tumor epithelialmesenchymal transition via brachyury-based vaccines. Advances in Cancer Research 128 69-93. (doi:10.1016/bs.acr.2015.04.001)
32. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP & Schlom J 2007 The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clinical Cancer Research 13 2471-2478. (doi:10.1158/1078-0432.CCR-06-2353)
33. Palena C, Hamilton DH & Fernando RI 2012 Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncology 8 713-722. (doi:10.2217/fon.12.59)
34. Palena C, Fernando RI & Hamilton DH 2014a An immunotherapeutic intervention against tumor progression: targeting a driver of the epithelial-to-mesenchymal transition. Oncoimmunology 3 e27220. (doi:10.4161/onci.27220)
35. Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, et al. 2014b Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. Journal of the National Cancer Institute 106 dju054. (doi:10.1093/jnci/dju054)
36. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology 27 1160-1167. (doi:10.1200/JCO.2008.18.1370)
37. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000 Molecular portraits of human breast tumours. Nature 406 747-752. (doi:10.1038/35021093)
38. Pinto F, Pertega-Gomes N, Pereira MS, Vizcaino JR, Monteiro P, Henrique RM, Baltazar F, Andrade RP & Reis RM 2014 T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clinical Cancer Research 20 4949-4961. (doi:10.1158/1078-0432.CCR-14-0421)
39. Pinto F, Campanella NC, Abrahao-Machado LF, Scapulatempo-Neto C, de Oliveira AT, Brito MJ, Andrade RP, Guimaraes DP & Reis RM 2015 The embryonic Brachyury transcription factor is a novel biomarker of GIST aggressiveness and poor survival. Gastric Cancer 19 651-659. (doi:10.1007/s10120-015-0505-0)
40. Prat A, Parker JS, Fan C & Perou CM 2012 PAM50 assay and the threegene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Research Treatment 135 301-306. (doi:10.1007/s10549-012-2143-0)
41. Reis-Filho JS & Tutt AN 2008 Triple negative tumours: A critical review. Histopathology 52 108-118. (doi:10.1111/j.1365-2559.2007.02889.x)
42. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton DH, Huang B, et al. 2012 Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clinical Cancer Research 18 3868-3879. (doi:10.1158/1078-0432.CCR-11-3211)
43. Sarkar D, Shields B, Davies ML, Muller J & Wakeman JA 2012 BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells. International Journal of Cancer 30 328-337. (doi:10.1002/ijc.26029)
44. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G & Palacios J 2008 Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Research 68 989-997. (doi:10.1158/0008-5472.CAN-07-2017)
45. Shao C, Zhang J, Fu J & Ling F 2015 The potential role of Brachyury in inducing epithelial-to-mesenchymal transition (EMT) and HIF-1alpha expression in breast cancer cells. Biochemical and Biophysical Research Communications 467 1083-1089. (doi:10.1016/j. bbrc.2015.09.076)
46. Thiery JP & Sleeman JP 2006 Complex networks orchestrate epithelialmesenchymal transitions. Nature Review Molecular Cell Biology 7 131-142. (doi:10.1038/nrm1835)